This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Freie Universitat Berlin. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Simko Sama: Innovator in Gene Delivery Technologies
Introduction
Simko Sama is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of gene delivery, focusing on enhancing transfection efficiency while minimizing cytotoxic effects. With a total of 2 patents, his work is paving the way for advancements in therapeutic applications.
Latest Patents
Sama's latest patents include an "Efficient gene delivery tool with a wide therapeutic margin." This invention relates to novel saponins that comprise acetyl residues on two of their sugar residues. These saponins significantly enhance transfection efficiency and exhibit much lower cytotoxic side effects compared to previously known saponins. Another notable patent is "Uses of a saponin and method for its isolation." This invention highlights the novel use of saponins with acetyl residues on one of their sugar residues, which remarkably improves transfection efficiency beyond that of known saponins and even Lipofectamin.
Career Highlights
Simko Sama is affiliated with Freie Universität Berlin, where he conducts research and develops innovative solutions in gene delivery. His work is characterized by a commitment to improving therapeutic outcomes through advanced biotechnological methods.
Collaborations
Sama collaborates with esteemed colleagues, including Alexander Weng and Matthias F Melzig, to further enhance the impact of his research in the scientific community.
Conclusion
Simko Sama's contributions to gene delivery technologies are noteworthy, as he continues to innovate and collaborate in the field. His patents reflect a dedication to improving therapeutic methods, which may lead to significant advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile